ANDA 211817, held by Eugia Pharma. Testosterone Cypionate.
As of Nov 16, 2026, ANDA 211817 (Testosterone Cypionate), held by Eugia Pharma, was first approved by FDA on Oct 20, 2023, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of Testosterone Cypionate Injection in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 20, 2023 | Original application | Approved | None posted |
| Testosterone Cypionate100MG/ML · injectable;injection | Testosterone Cypionate | Rx |
| Testosterone Cypionate200MG/ML · injectable;injection | Testosterone Cypionate | Rx |
| Testosterone Cypionate200MG/ML · injectable;injection | Testosterone Cypionate | Rx |
| Jul 11, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 20, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters